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Abstract: Background: Interpretation of hemoglobin A1c (HbA1c) levels may be confounded by
spurious results in anemic persons, but its degree is not well-established. Methods: We used an
employer-based health insurance database, containing health checkup data and medical claims
data; both were linked via a unique identifier of each beneficiary. This study included persons aged
18–75 years who participated in health checkups, with a confirmed or suspected diagnosis of diabetes.
The relationship between hemoglobin (Hb) and HbA1c is shown in a spline curve using a machine
learning technique accounting for patient factors and within-person correlations. Spline curves
were also shown in several sub-populations. Results: Overall, a decreased Hb value was associated
with a lower HbA1c value, but the extent differed among populations. In the whole cohort of the
type-2 diabetes group (55,420 persons), the curve was generally a plateau in the persons with a Hb
value <120–130 g/L. Among the 18,478 persons with HbA1c around 48 mmol/mol, we observed a
liner trend. Among the current glucose-lowering medication users (6253 persons), we found a right
upward curve. Conclusions: The relationship between Hb and HbA1c may not be straightforward,
varying among populations of different clinical interest. Our results indicate that a simple formulation
between the Hb and HbA1c values is unlikely.
Keywords: anemia; diabetes mellitus; spline curve; generalized additive mixed model;
machine learning
1. Introduction
The number of persons with diabetes is rapidly increasing worldwide, particularly with type-2
diabetes mellitus (T2DM) [1]. The number of persons with diabetes is expected to increase from 425
million in 2018 to 642 million by 2040, with T2DM accounting for more than 90% of these persons [2].
The increase of T2DM is supposed to be associated with an increase in obesity, sedentary lifestyle,
and energy-dense diets [3]. Although the data are somewhat inconsistent, the incidence and prevalence
of type 1 diabetes mellitus (T1DM) are also reported to be increasing [4].
Hemoglobin A1c (HbA1c) is widely used as measure for the diagnosis and management of
diabetes [5]. The advantages of HbA1c over other metrics of glucose control monitoring are its
convenience for patient and the ease of sample collection; HbA1c sampling can be obtained at any
time, requires no patient preparation (e.g., fasting), and is relatively stable at room temperature [6].
However, the HbA1c value may exhibit spurious results influenced by non-glycemic factors including
anemia, hemoglobin variants, or chronic illness (e.g., nutrient deficiency, liver failure, and end-stage
renal disease) [7]. Among these factors, the degree to which the HbA1c value is confounded by anemia
remains unknown. For example, although most of the earlier works found that iron deficiency anemia
J. Clin. Med. 2018, 7, 539; doi:10.3390/jcm7120539 www.mdpi.com/journal/jcm
J. Clin. Med. 2018, 7, 539 2 of 9
was related to elevated HbA1c levels [8], the reported degree varied from 3 to 23 mmol/mol [9–12].
These comparisons were made between different persons with and without iron deficiency anemia,
or between the same persons before and after iron replacement. The paucity of the existing knowledge
is partly because there has been only a limited number of existing studies to date, with low participant
numbers [8]. Also, because of the different definitions used for anemia in these previous studies,
the interpretation of the findings may be complicated.
We hypothesized that graphical presentation using continuous values for hemoglobin (Hb) and
HbA1c without assumption would be easy-to-interpret. In addition, we assumed that a large number
of participants would increase the generalizability. For these backgrounds, the present study sought to
graphically describe the associations between the Hb and HbA1c values, using a large-scale regular
health checkup data of the Japanese population with or without diabetes.
2. Experimental Section
2.1. Participants
We used an employer-based health insurance database in Japan, compiled by a commercial data
vendor (Japan Medical Data Center, Tokyo, Japan), which included the health records of a total of
4.8 million individuals from nearly 100 insurances [13]. The database included health checkup data
and medical claims data, and both of these data were linked via a unique identifier assigned to each
beneficiary. From this database, the data vendor extracted persons (1) who had a data record of at least
health checkup, and (2) who had at least one claims record of confirmed or suspected diagnosis of
diabetes during 2005–2013.
In Japan, the annual health checkup has been recommended for employees since the 1970s,
and for all persons aged 40–74 years since 2009. Thus, this study involved the checkup data of (1)
employees of all-ages during 2005–2013, as well as of (2) their family members aged 40–74 years during
2009–2013. The health checkup data typically included valuables such as Hb, HbA1c, fasting glucose
level, body mass index, and self-reported current smoking status, but it did not include the serum
ferritin level or reticulocyte count. We also utilized the prescription data and diagnostic records of the
claims database.
From the dataset extracted by the data vendor, we created two separate cohorts for T2DM and
T1DM. The T2DM cohort included at least one diagnostic record of T2DM (International Classification
of Diseases, 10th Revision (ICD-10) code: E11). In the Japanese health insurance system, records
of unconfirmed diagnosis are acceptable for claims purposes (e.g., recorded as “suspected” T2DM);
this kind of diagnosis was often made when performing a laboratory examination for persons at
risk of developing the condition. This study did not exclude persons with unconfirmed T2DM,
so that this cohort represented a mixture of persons with confirmed T2DM and those at risk of
T2DM. From this T2DM cohort, we formed three sub-cohorts. First, we identified persons undergoing
current treatment who had glucose-lowering agents, within 90 days of a health checkup in an
outpatient setting. The second sub-cohort included persons with HbA1c values around a diagnostic
threshold of 48 mmol/mol (37–58 mmol/mol). The third cohort comprised persons who received
iron-supplementation. We identified persons with an outpatient prescription of iron preparation within
90 days of a health checkup. Because the data of serum ferritin—the standard diagnostic measure
of iron deficiency anemia—were lacking in the health checkup data, we assumed that the persons
with active iron supplementation represented persons with iron deficiency anemia. We additionally
calculated the mean corpuscular volume (MCV) for each person, in order to see how likely it was that
the anemia was caused by an iron deficiency in our population; the results are presented in Figure 1.
Finally, the criteria for T1DM cohort were as follows: (1) having the diagnostic code for T1DM (ICD-10:
E10); (2) receiving insulin maintenance therapy, identified by an insulin prescription record from at
least two separate outpatient encounters; and (3) excluding persons with a suspected diagnosis. For the
T1DM cohort, a sub-cohort was not created.
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2.2. Statistical Analysis
The participant characteristics were summarized as descriptive statistics. The relationship
between the Hb and HbA1c values was displayed in a spline curve constructed without a pre-specified
relationship between the variables (e.g., linearity). We developed spline curves using a general additive
mixed effects model adjusting for age, sex, fasting glucose level, body mass index, smoking status,
and within-person correlation [14]. Persons with a high Hb or HbA1c level at baseline tended to have
high levels of these values in the later checkup tests, and vice versa; a mixed effects model was used
to account for these within-person correlations in the repeated measures. Participants without the
aforementioned covariates were excluded from the analysis. We created several spline curves in all
of the cohorts defined above. Although model computations were done using a high-performance
computer with 128 GB available in RAM memory, some computations were terminated because of a
memory limit. In such cases, we adequately used a random sampling of the participants (e.g., 20%)
for computation; we have confirmed that the graphical relationship between Hb and HbA1c was not
affected by these different sampling sets (data not shown).
All of the statistical analyses were done with R statistical software version 3.43 (https://www.
r-project.org/) with the use of mgcv package version 1.8-23 for computing generalized additive
mixed model.
3. Results
After excluding 24.9% of the participants (n = 18,338) with missing data, this study enrolled 55,420
persons in the T2DM cohort and 598 persons in the T1DM cohort, with a mean of 2.7 checkup records
for each person. Table 1 summaries the characteristics of the study cohort.



















Cohort (n = 956)
Age 3 (years) 46.5 (10.7) 51.2 (9.3) 51.4 (9.3) 44.2 (8.3) 48.4 (10.1) 44.2 (8.3)
Sex (male) 59.4% 66.4% 77.4% 17.8% 72.2% 17.8%
BMI 3 (kg/m2) 23.8 (4.3) 25.3 (4.5) 25.9 (4.7) 22.3 (4.2) 24.7 (4.7) 22.3 (4.2)
Hb 4 (g/L) 143 (16) 144 (16) 148 (15) 118 (19) 141 (17) 11.8 (19)
HbA1c 3
(mmol/mol)
35 (11) 41 (5) 52 (16) 33 (9) 63 (21) 33 (9)
fBG 3 (mg/dL) 104 (33) 114 (27) 149 (55) 97 (29) 168 (74) 97 (29)
Smoking 32.1% 32.2% 37.9% 21.8% 40.3% 21.8%
1: Persons with T2DM; 2: 48 mmol/mol in IFCC unit; 3: Current glucose-lowering drug users; 4: Data are shown as
mean with standard deviation; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus; BMI, body mass
index; Hb, hemoglobin; HbA1c, hemoglobin A1c; fBG, fasting blood glucose.
In our study cohort, there was a trend towards a lower MCV in anemic persons (Figure 1).
Overall, a decreased Hb value was associated with a lower HbA1c value, after adjusting the
baseline characteristics, but the degree of this trend differed among populations. In the overall T2DM
cohort, the relationship between the Hb and HbA1c value was generally a plateau in persons with a
Hb value <120–130 g/L, and had a right upward trend above this range (Figure 2).
For the T2DM sub-cohort with an HbA1c diagnostic threshold close to that of diabetes (i.e.,
48 mmol/mol), we noted a liner upward trend (Figure 3).
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Figure 3. The relationship between Hb and HbA1c value in persons with HbA1c values of around 48 
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Figure 4. The relationship between Hb and HbA1c values in persons with glucose-lowering 
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Figure 3. The relationship between Hb and HbA1c value in persons with HbA1c values of around
48 mmol/mol (n = 18,478). Graph was created with a 75% random sampling.
In the T2DM sub-cohort that included persons currently taking glucose-lowering medication
(6253 persons), we found a global right upper tend (Figure 4).
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The relationship in the T2DM sub-cohort taking iron-supplementation (956 persons) showed a
U-shaped relationship (Figure 5).
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We also found that the relationship between Hb and HbA1c showed a linear trend among
598 persons in the T1DM cohort (Figure 6)
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4. Disc ssion
We found that the relationship between Hb and HbA1c was complicated. Overall, the HbA1c
values in anemic persons were lower than those in non-anemic persons (i.e., persons with normal
or high Hb), but its degree varied among populations. According to a systematic review in 2015,
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establishing the degree of anemia on the reliability of HbA1c is inconclusive [8]. This review identified
12 relevant studies, but the numbers of patients were typically small in each study. Another caveat of
the prior studies was that they compared two groups, divided by a specific cut-off value for anemia.
Such a categorization may miss within-group variations [15], and we indeed observed different patterns
within the anemic populations (right side of Figures 2–6) or within the non-anemic populations (left
side of Figures 2–6).
The influence of anemia on HbA1c concentration can be cause-specific. For example,
iron-deficiency may shift HbA1c slightly upward, whereas other forms of anemia or the recovery phase
from iron deficiency anemia are associated with lower HbA1c [16]. We could not determine the cause of
anemia in each participant, because of the absence of markers (e.g., ferritin level) in the health checkup
data. As shown in Figure 1, a lower MCV in anemic persons suggests that anemia was largely due to
the iron-deficiency. However, it is possible that the anemic populations in our study were a mixture of
persons suffering from iron-deficiency anemia with or without treatment, and those of other types
of anemia. Previous studies focused on the specific types of anemia, such as nutritional-deficiency
or menstruation [4], leading to specific results forming a selected but homogenous population at
the cost of generalizability. On the hand, in this study, the data from diverse populations lead to
generalizability, but we may have overlooked the relationship between anemia and HbA1c values in
certain populations.
We observed different response patterns of Hb and HbA1c among different populations,
unexpectedly. Different baseline characteristics other than the Hb and HbA1c valuables may be
the cause, although we have statistically addressed these potential confounders where possible,
by applying a mixed effects model. Our research suggests that it will be challenging to develop a
simple correction formula between anemia and HbA1c that is applicable to a universal population.
For these reasons, the present study may give warning that treatment decisions based solely on
HbA1c measurement without the consideration of other clinical data may lead to overdiagnosis or
overtreatment, reinforcing the statement in the recent guideline [9]. This study also suggests that it is
difficult to define the optimal threshold of anemia, and to explore the relationship between anemia and
HbA1c. This implicates that, in future studies, the Hb value should be treated as a continuous value in
order to minimize the loss of information by categorization [17].
Our study exhibits an explanatory relationship between the Hb and HbA1c values analyzed by
a data-driven approach, rather than by establishing causality, yet our findings are, not fully, but to
some extent, consistent with previous researches. Firstly, one recent study found that the degree of
iron deficiency anemia influenced the HbA1c level [18], in which severe anemia was associated with
a higher HbA1c level. This may explain the phenomena in the left side of Figure 5, showing a left
upward trend among persons receiving active treatment of iron supplementation. Secondly, our graphs
consistently showed a right upward trend. In polycythemia, the HbA1c may increase because of a
longer red blood cell lifespan [19], and the relationship between polycythemia and elevated HbA1c
was reported in some literature of rare, congenital hemoglobin variants [20,21]. The right upward
trends in the Figures could be explained by such a theoretical ground.
Here, we discuss limitations of our study. First, it is unclear whether our results are applicable
to other populations, such as elderly persons or other ethnic groups. For example, among persons
with type 1 diabetes, the overestimation of HbA1c levels could occur in black persons compared with
white persons, possibly because of racial differences in the hemoglobin glycation [22]. In our study,
participants were limited to the Japanese population, and a different response pattern between Hb
and HbA1c might found in other ethnic groups. Also, our study population was relatively young.
Accordingly, it is unknown whether our findings are replicable in other settings. Second, we could not
control the interlaboratory variations of laboratory measures, if any. These limitations highlight the
need for more research on this topic.
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5. Conclusions
We presented the graphical overview on the relationship between Hb and HbA1c from large-scale
data in Japan. We found out that to what degree anemia affected the HbA1c was varied among the
population, and the relationship is unlikely to be easily formulated nor converted. Our study did
not reveal the causality, and the data from the unselected populations might be of limited value for
individual-level use; these issues would be an area for future research. Our findings imply that the
management of diabetes relying solely on the HbA1c value warrants careful consideration in a subset
of populations, such as in persons with anemia.
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